Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 24491088)

1.

Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.

Lindström V, Ihse E, Fagerqvist T, Bergström J, Nordström E, Möller C, Lannfelt L, Ingelsson M.

Immunotherapy. 2014;6(2):141-53. doi: 10.2217/imt.13.162. Review.

PMID:
24491088
2.

Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.

Fagerqvist T, Lindström V, Nordström E, Lord A, Tucker SM, Su X, Sahlin C, Kasrayan A, Andersson J, Welander H, Näsström T, Holmquist M, Schell H, Kahle PJ, Kalimo H, Möller C, Gellerfors P, Lannfelt L, Bergström J, Ingelsson M.

J Neurochem. 2013 Jul;126(1):131-44. doi: 10.1111/jnc.12175. Epub 2013 Feb 27.

PMID:
23363402
3.

Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.

Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ.

J Neurosci. 2012 Sep 26;32(39):13454-69.

4.

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.

Lindström V, Fagerqvist T, Nordström E, Eriksson F, Lord A, Tucker S, Andersson J, Johannesson M, Schell H, Kahle PJ, Möller C, Gellerfors P, Bergström J, Lannfelt L, Ingelsson M.

Neurobiol Dis. 2014 Sep;69:134-43. doi: 10.1016/j.nbd.2014.05.009. Epub 2014 May 20.

PMID:
24851801
5.

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D.

PLoS One. 2011 Apr 29;6(4):e19338. doi: 10.1371/journal.pone.0019338.

6.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

7.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

8.

Targeting alpha-synuclein for the treatment of Parkinson's disease.

Rohn TT.

CNS Neurol Disord Drug Targets. 2012 Mar;11(2):174-9. Review.

PMID:
22483285
9.

Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.

Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, Lee VM.

Cell Rep. 2014 Jun 26;7(6):2054-65. doi: 10.1016/j.celrep.2014.05.033. Epub 2014 Jun 12.

10.

Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study.

Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, Davtyan A, Cribbs DH, Agadjanyan MG.

Neurosci Lett. 2014 Feb 7;560:86-91. doi: 10.1016/j.neulet.2013.12.028. Epub 2013 Dec 19.

11.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
12.

Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice.

Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, Wakabayashi K.

Acta Neuropathol. 2010 Aug;120(2):145-54. doi: 10.1007/s00401-010-0676-z. Epub 2010 Mar 26.

PMID:
20339856
13.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
14.
15.

The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Spillantini MG, Goedert M.

Ann N Y Acad Sci. 2000;920:16-27. Review.

PMID:
11193145
16.

Parkinson disease: A monoclonal antibody targeting misfolded α-synuclein has therapeutic potential in Parkinson disease.

Wood H.

Nat Rev Neurol. 2014 Aug;10(8):426. doi: 10.1038/nrneurol.2014.119. Epub 2014 Jul 8. No abstract available.

PMID:
25002110
17.

Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.

Eyal A, Engelender S.

Cell Cycle. 2006 Sep;5(18):2082-6. Epub 2006 Sep 15. Review.

18.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
19.

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Valera E, Masliah E.

Pharmacol Ther. 2013 Jun;138(3):311-22. doi: 10.1016/j.pharmthera.2013.01.013. Epub 2013 Feb 4. Review.

20.

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.

Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA.

PLoS One. 2013 Aug 23;8(8):e71634. doi: 10.1371/journal.pone.0071634. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk